The Safety and Efficacy of TET Enema in the Treatment of UC

Sponsor
The Second Hospital of Nanjing Medical University (Other)
Overall Status
Unknown status
CT.gov ID
NCT03917095
Collaborator
(none)
75
1
5
1.5
49.6

Study Details

Study Description

Brief Summary

Colonic Transendoscopic enteral Tubing(TET) is a novel, safe, convenient, and reliable procedure for Fecal Microbiota Transplantation(FMT).This clinical trail aims to evaluate the efficacy and safety of Mesalazine and Compound Glutamine enema in the treatment of Ulcerative Colitis through Colonic TET.

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

Enema is a conventional treatment for Ulcerative Colitis(UC). Mesalazine is suitable for the patients with mild to moderate UC.But for the UC with extending lesions, the conventional anema with Mesalazine or other medicine can not very effective.Colonic Transendoscopic enteral Tubing(TET) is a novel, safe, convenient, and reliable procedure for Fecal Microbiota Transplantation(FMT).Compared with the conventional enema, which is only used for local administration, the Colonic TET enema can achieve total colonic administration.This study aims to evaluate the efficacy and safety of Colonic TET for UC.Patients in this study will be divided into 5 groups according to certain criteria: the Mesalazine conventional enema group, the Mesalazine TET enema group, the Compound Glutamine conventional enema group, the Compound Glutamine TET enema group, the Mesalazine and Compound Glutamine TET enema group.Each group was given enema for 7 days.The primary outcome measure was the clinical remission efficacy rate in each group. The secondary outcome measure was the safety of TET.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
75 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Other
Official Title:
Mesalazine and Compound Glutamin Enema for the Treatment of Ulcerative Colitis Through Colonic Transendoscopic Enteral Tubing: A Multicenter, Randomized, Controlled Trail
Anticipated Study Start Date :
May 15, 2019
Anticipated Primary Completion Date :
Jun 15, 2019
Anticipated Study Completion Date :
Jun 30, 2019

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Mesalazine conventional enema

Participants undergo the conventional enema of Mesalazine Enemas (4g) for one week.

Drug: Mesalazine
The medications were infused into the colon
Other Names:
  • Mesalazine Enema Product
  • Experimental: Mesalazine TET enema

    Participants undergo the TET enema of Mesalazine Enemas (4g) for one week.

    Device: The Colonic Transendoscopic enteral Tubing.
    The medications were infused into the colon through the Colonic Transendoscopic enteral Tubing(TET).

    Drug: Mesalazine
    The medications were infused into the colon
    Other Names:
  • Mesalazine Enema Product
  • Active Comparator: Compound Glutamine conventional enema

    Participants undergo the conventional enema of Compound Glutamine (24 tablets of the drug were dissolved in 50ml normal saline) for one week.

    Drug: Glutamine
    The medications were infused into the colon
    Other Names:
  • Glutamine Product
  • Experimental: Compound Glutamine TET enema

    Participants undergo the TET enema of Compound Glutamine (24 tablets of the drug were dissolved in 50ml normal saline) for one week.

    Device: The Colonic Transendoscopic enteral Tubing.
    The medications were infused into the colon through the Colonic Transendoscopic enteral Tubing(TET).

    Drug: Glutamine
    The medications were infused into the colon
    Other Names:
  • Glutamine Product
  • Experimental: Compound Glutamine and Mesalazine TET enema

    Participants undergo the TET enema of Mesalazine(4g) and Compound Glutamine (24 tablets of the drug were dissolved in 50ml normal saline) for one week.

    Device: The Colonic Transendoscopic enteral Tubing.
    The medications were infused into the colon through the Colonic Transendoscopic enteral Tubing(TET).

    Drug: Glutamine
    The medications were infused into the colon
    Other Names:
  • Glutamine Product
  • Drug: Mesalazine
    The medications were infused into the colon
    Other Names:
  • Mesalazine Enema Product
  • Outcome Measures

    Primary Outcome Measures

    1. Clinical remission rate [10-days]

      The frequency of defecation and hematochezia score were both zero

    2. The effective rate [10-days]

      Part of the total Mayo score was 3 points lower than the baseline

    Secondary Outcome Measures

    1. Adverse events [10-days]

      Number of participants with treatment-related adverse events

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Male or female patients aged between 18 and 65

    2. Patients with chronic relapsed mild to moderate active Ulcerative Colitis(left semicolon or extending colonic lesions)

    3. Patients who can fully understand this study and voluntarily sign an informed consent;

    4. Accept re-examination, follow-up examination and specimen retention in time

    5. Suitable for colonoscopy and colonic TET;

    6. A history of using Mesalazine and Compound Glutamine safely

    Exclusion Criteria:
    1. Anti-tumor necrosis factor or methotrexate was used within the first 8 weeks

    2. Cyclosporine was used within 4 weeks

    3. Antibiotics or probiotics was used within 4 weeks

    4. Patients with risk of toxic megacolon, colon cancer or atypical hyperplasia found in pathology

    5. History of colon surgery

    6. Patients with moderate or severe renal impairment ,abnormal liver function,severe hypertension and cerebrovascular accident

    7. Accompanied by other serious diseases, such as cancer or AIDS, that may hinder their enrollment or affect their survival

    8. Patients with anxiety, depression, mental or legal disabilities

    9. History of suspected or proven alcohol/drug abuse

    10. Patients with explosive, massive bloody stools and severe illness who cannot tolerate the colonoscopy

    11. Patients who are allergic to salicylic acid or aspirin

    12. Patients with food allergies

    13. Patients who are preparing to become pregnant during the study period

    14. Patients considered by the researchers as unsuitable for enrollment

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University Nanjing Jiangsu China 210011

    Sponsors and Collaborators

    • The Second Hospital of Nanjing Medical University

    Investigators

    • Principal Investigator: Faming Zhang, MD,PhD, The Second Hospital of Nanjing Medical University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Faming Zhang, Professor, Gastroenterology, The Second Hospital of Nanjing Medical University
    ClinicalTrials.gov Identifier:
    NCT03917095
    Other Study ID Numbers:
    • TET-CN-190408
    First Posted:
    Apr 16, 2019
    Last Update Posted:
    May 15, 2019
    Last Verified:
    May 1, 2019
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Faming Zhang, Professor, Gastroenterology, The Second Hospital of Nanjing Medical University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 15, 2019